ReviewJournal of molecular and cellular cardiology2011
β₂ AR agonists in treatment of chronic heart failure: long path to translation.
Review in Journal of molecular and cellular cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Cardioprotective effect of histamine H2 antagonists in congestive heart failure: A systematic review and meta-analysis.Medicine · 2018Pooled it
- G protein coupled receptor in apoptosis and apoptotic cell clearance.FASEB bioAdvances · 2024Review
- Internalized β2-Adrenergic Receptors Oppose PLC-Dependent Hypertrophic Signaling.Circulation research · 2024Article
- Biased activation of βCell death discovery · 2021Article
- Subtype-dependent regulation of Gβγ signalling.Cellular signalling · 2021Review
- Beta3-Adrenergic Receptor Activation Alleviates Cardiac Dysfunction in Cardiac Hypertrophy by Regulating Oxidative Stress.Oxidative medicine and cellular longevity · 2021Article
- A mini review of inhaled beta 2 agonists in acute decompensated heart failure requiring respiratory support.Pulmonary and critical care medicine · 2019Article
- Transcriptomic Validation of the Protective Effects of Aqueous Bark Extract ofFrontiers in pharmacology · 2019Article
- Raf kinase inhibitor protein mediates myocardial fibrosis under conditions of enhanced myocardial oxidative stress.Basic research in cardiology · 2018Article
- Raf kinase inhibitor protein: lessons of a better way for β-adrenergic receptor activation in the heart.The Journal of physiology · 2017Review
- Molecular dynamics analysis to evaluate docking pose prediction.Biophysics and physicobiology · 2016Article
- A New Pathway for Sympathetic Cardioprotection in Heart Failure.Circulation research · 2015Article
- Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling.British journal of pharmacology · 2015Article
- Pathological hypertrophy reverses β2-adrenergic receptor-induced angiogenesis in mouse heart.Physiological reports · 2015Article
- Insular infarct size but not levosimendan influenced myocardial injury triggered by cerebral ischemia in rats.Experimental brain research · 2015Article
- The switching role of β-adrenergic receptor signalling in cell survival or death decision of cardiomyocytes.Nature communications · 2014Article
- cAMP signaling in subcellular compartments.Pharmacology & therapeutics · 2014Review
- Introduction to the series: challenges and opportunities in pediatric heart failure and transplantation.Circulation · 2014Article
- β-Adrenergic regulation of cardiac progenitor cell death versus survival and proliferation.Circulation research · 2013Article
- The role of G protein coupled receptor kinases in neurocardiovascular pathophysiology.Archives of medical science : AMS · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
The main clinical manifestations of advanced chronic heart failure (CHF), e.g. in dilated cardiomyopathy (DCM), are reduced systolic and diastolic functions, increased arterial elastance and arterio-ventricular uncoupling, accompanied and exacerbated by an excessive sympathetic activation and extensive abnormalities in the βAR signaling. Loss of cardiomyocytes due to apoptosis is one mechanism that undoubtedly contributes to cardiac remodeling and functional deterioration associated with dilated cardiomyopathy (DCM). Research during the last decade on the single cardiomyocyte level strongly suggested that selective stimulation of β(1) AR activates the proapoptotic signaling pathways, while selective stimulation of β(2) AR is antiapoptotic, but its precise mechanisms remain to be elucidated. Extensive research in the rat model of DCM following induction of myocardial infarction (MI) showed that prolonged treatment with of β(2) AR agonist, fenoterol, in combination with a β(1) AR blocker, metoprolol, is more effective than β(1) AR blocker alone and as effective as β(1) AR blocker with ACE inhibitor with respect to survival and cardiac remodeling. This combined regimen of β(2) AR agonists and a β(1) AR blocker might be considered for clinical testing as alternative or adjunct therapy to currently acceptable CHF arsenal. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.